Edition:
United States

Alimera Sciences Inc (ALIM.O)

ALIM.O on Consolidated Issue listed on NASDAQ Global Market

1.25USD
17 Nov 2017
Change (% chg)

$0.03 (+2.46%)
Prev Close
$1.22
Open
$1.21
Day's High
$1.25
Day's Low
$1.21
Volume
56,411
Avg. Vol
232,151
52-wk High
$1.72
52-wk Low
$1.04

Chart for

About

Alimera Sciences, Inc. (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina. The... (more)

Overall

Beta: 2.19
Market Cap(Mil.): $86.44
Shares Outstanding(Mil.): 69.15
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.35 15.79
EPS (TTM): -- -- --
ROI: -- 15.11 12.01
ROE: -- 16.52 15.91

BRIEF-Alimera Sciences Inc reports qtrly loss per share ‍$0.08​

* Alimera Sciences Inc reports third quarter 2017 financial results

Nov 01 2017

BRIEF-Alimera Sciences files for mixed shelf of up to $100 mln‍​

* Alimera Sciences Inc files for mixed shelf of up to $100 million – SEC filing ‍​ Source text - (http://bit.ly/2yCWftF) Further company coverage:

Oct 23 2017

BRIEF-Alimera Sciences ‍announces Iluvien now available in Ireland​

* Alimera Sciences Inc - ‍Announces Iluvien now available in Ireland​ Source text for Eikon: Further company coverage:

Sep 12 2017

BRIEF-Alimera Sciences signs agreement for distribution of Iluvien in France

* Alimera Sciences signs agreement for exclusive distributor of Iluvien in France

Aug 29 2017

BRIEF-Alimera Sciences Q2 ‍net loss per share $0.04​

* Alimera Sciences reports second quarter 2017 financial results

Aug 02 2017

BRIEF-Alimera Sciences announces real-world audit data supporting positive benefits of iluvien treatment

* Alimera Sciences announces real-world audit data supporting the positive benefits of iluvien treatment

Jul 25 2017

BRIEF-Alimera Sciences announces italian patients now being treated with Iluvien

* Alimera Sciences announces italian patients now being treated with Iluvien® Source text for Eikon: Further company coverage:

Jul 12 2017

BRIEF-pSivida- in connection with new collaboration agreement, Alimera forgave $10 mln of co's share of losses associated with commercialization of ILUVIEN

* pSivida - in connection with new collaboration agreement, alimera forgave $10 million of co's share of losses associated with commercialization of ILUVIEN

Jul 10 2017

Competitors

Earnings vs. Estimates